TAK logo

TAK
Takeda Pharmaceutical Co Ltd (ADR)

3,713
Mkt Cap
$52.7B
Volume
1.85M
52W High
$18.90
52W Low
$12.99
PE Ratio
40.43
TAK Fundamentals
Price
$16.45
Prev Close
$16.68
Open
$16.39
50D MA
$17.44
Beta
0.27
Avg. Volume
2.86M
EPS (Annual)
$0.404
P/B
1.08
Rev/Employee
$630,074.32
$86,320.34
Loading...
Loading...
News
all
press releases
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) said Tuesday a jury in the U.S. District Court for the District of Massachusetts returned a verdict against the company in the AMITIZA or lubiprostone...
Nasdaq News: Markets·3d ago
News Placeholder
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
A class-action lawsuit against Takeda Pharmaceuticals USA Inc. on behalf of direct purchasers of Amitiza and its generic equivalents ended today when a jury returned a verdict finding the pharma...
Business Wire·3d ago
News Placeholder
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management...
Business Wire·9d ago
News Placeholder
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Zacks·13d ago
News Placeholder
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Zacks·16d ago
News Placeholder
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated...
Business Wire·17d ago
News Placeholder
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·21d ago
News Placeholder
China Universal Asset Management Co. Ltd. Takes Position in Takeda Pharmaceutical Co. $TAK
China Universal Asset Management Co. Ltd. bought a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent Form 13F filing...
MarketBeat·26d ago
News Placeholder
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
Zacks·27d ago
<
1
2
...
>

Latest TAK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.